ADIPOSA

The purpose of this research is to understand the effects of medication, Bexagliflozin, on obstructive sleep apnea. We are investigating how Bexagliflozin may improve obstructive sleep apnea by evaluating multiple anatomic and non-anatomic physiological traits causing obstructive sleep apnea. We will also investigate how Bexagliflozin may improve other conditions associated with obstructive sleep apnea. Bexagliflozin is under a medication class sodium glucose cotransporter 2 inhibitor (SGLT2i), it is FDA-approved for diabetes and may be a potential therapy for obstructive sleep apnea.

https://clinicaltrials.gov/study/NCT05612594